These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 25741818)
1. Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates. Burns KE; Robinson MK; Thévenin D Mol Pharm; 2015 Apr; 12(4):1250-8. PubMed ID: 25741818 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models. Burns KE; Hensley H; Robinson MK; Thévenin D Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942 [TBL] [Abstract][Full Text] [Related]
3. Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors. Wyatt LC; Moshnikova A; Crawford T; Engelman DM; Andreev OA; Reshetnyak YK Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2811-E2818. PubMed ID: 29507241 [TBL] [Abstract][Full Text] [Related]
4. pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1. Yu M; Chen Y; Wang Z; Ding X Breast Cancer Res Treat; 2020 Apr; 180(2):379-384. PubMed ID: 32034579 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model. Wu F; Chen Y; Li D; Wang Z; Yu M Mol Imaging Biol; 2022 Aug; 24(4):570-579. PubMed ID: 35006491 [TBL] [Abstract][Full Text] [Related]
6. Divalent Cations and Lipid Composition Modulate Membrane Insertion and Cancer-Targeting Action of pHLIP. Vasquez-Montes V; Gerhart J; Thévenin D; Ladokhin AS J Mol Biol; 2019 Dec; 431(24):5004-5018. PubMed ID: 31689432 [TBL] [Abstract][Full Text] [Related]
7. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Yap ML; McFadyen JD; Wang X; Ziegler M; Chen YC; Willcox A; Nowell CJ; Scott AM; Sloan EK; Hogarth PM; Pietersz GA; Peter K Theranostics; 2019; 9(4):1154-1169. PubMed ID: 30867822 [No Abstract] [Full Text] [Related]
8. Ku80-Targeted pH-Sensitive Peptide-PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation. Kaplan AR; Pham H; Liu Y; Oyaghire S; Bahal R; Engelman DM; Glazer PM Mol Cancer Res; 2020 Jun; 18(6):873-882. PubMed ID: 32098827 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modeling reveals parameters that govern tumor targeting and delivery by a pH-Low Insertion Peptide (pHLIP). Svoronos AA; Engelman DM Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443162 [TBL] [Abstract][Full Text] [Related]
11. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436 [TBL] [Abstract][Full Text] [Related]
12. Comparison of lipid-dependent bilayer insertion of pHLIP and its P20G variant. Vasquez-Montes V; Gerhart J; King KE; Thévenin D; Ladokhin AS Biochim Biophys Acta Biomembr; 2018 Feb; 1860(2):534-543. PubMed ID: 29138065 [TBL] [Abstract][Full Text] [Related]
13. Noncanonical amino acids to improve the pH response of pHLIP insertion at tumor acidity. Onyango JO; Chung MS; Eng CH; Klees LM; Langenbacher R; Yao L; An M Angew Chem Int Ed Engl; 2015 Mar; 54(12):3658-3663. PubMed ID: 25650762 [TBL] [Abstract][Full Text] [Related]
15. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer. Chung SW; Cho YS; Choi JU; Kim HR; Won TH; Kim SY; Byun Y Biomaterials; 2019 Feb; 192():109-117. PubMed ID: 30447398 [TBL] [Abstract][Full Text] [Related]
16. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE. Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241 [TBL] [Abstract][Full Text] [Related]
17. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Temming K; Meyer DL; Zabinski R; Dijkers EC; Poelstra K; Molema G; Kok RJ Bioconjug Chem; 2006; 17(6):1385-94. PubMed ID: 17105215 [TBL] [Abstract][Full Text] [Related]
20. Cyclic RGD-Peptide-Functionalized Polylipopeptide Micelles for Enhanced Loading and Targeted Delivery of Monomethyl Auristatin E. Qiu M; Wang X; Sun H; Zhang J; Deng C; Zhong Z Mol Pharm; 2018 Nov; 15(11):4854-4861. PubMed ID: 30259747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]